Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact
Complements Presence In Ex Vivo And Cell Therapy
Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.
